| Theme | Clinical Management of Esophageal Cancer 2017 -- Current Status and Issues | |
|---|---|---|
| Title | Therapy for Advanced and Recurrent Esophageal Cancer | |
| Publish Date | 2017/08 | |
| Author | Yuji Inagaki | Gastrointestinal Medical Oncology Division, National Cancer Center Hospital |
| Author | Atsuo Takashima | Gastrointestinal Medical Oncology Division, National Cancer Center Hospital |
| Author | Narikazu Boku | Gastrointestinal Medical Oncology Division, National Cancer Center Hospital |
| [ Summary ] | Definitive chemoradiotherapy is a standard treatment for patients with locally advanced esophageal squamous cell carcinoma who are ineligible for surgery. For decades, the first‒line treatment for metastatic esophageal cancer has been 5‒FU and cisplatin, and taxanes are used as second line chemotherapy. New effective therapies are urgently needed ; as such, some clinical trials for esophageal cancer are underway. | |